Grant: Team Grant: NEURON
Université Laval
$100,000.00
Multi-scale exploration of autoantibodies against synaptic receptors
EF 2018-19
Résumé
Psychotic disorders (PDs) encompassing schizophrenia and bipolar disorders, are major health problems worldwide. Growing evidence suggest that these major psychoses have a neurodevelopmental component involving in particular synaptic imbalance mostly between glutamatergic and dopaminergic neurotransmitter systems. However, due to their complexity our understanding of PDs remains limited. It is well-established that several converging factors are involved in these complex PDs, among which immune status, including autoimmunity, are particularly relevant. A role for autoimmune dysfunction in PDs, reported in schizophrenia almost a century ago, is supported by specific autoimmune responses to selfantigens identified in particular in PD. The importance of autoimmunity in major psychosis has been strongly reinforced as a number of syndromes characterized by global encephalopathy and by more focal psychiatric symptoms was found to result from autoimmune dysfunction, caused by anti-neuronal antibodies that alter synaptic transmission, such as NMDARAb in encephalitis. Thus, the role of the autoimmunity against neuronal receptor targets in the pathogenesis of PDs has gained tremendous support over the last years and urgently requires multidisciplinary in-depth investigations to unravel the molecular mechanisms underlying psychosis and offer new therapeutic strategies. We identified that almost 20% of patients diagnosed with schizophrenia are seropositive for these autoantibodies, opening therapeutical options for these patients. Here, we plan to tackle such a major challenge in a unique, complementary and synergistic consortium of clinical and basic research experts, who strongly contributed to our current understanding of autoimmunity in brain disorders. Our objective is to uncover how NMDAR-Ab underliesPDs in seropositive NMDAR-Ab patients, using a unique and multi-scale combination of experimental approaches, from pre-clinical experiments to clinical exploration.
Programme
Team Grant: NEURON
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
387320
Name
Marquet Pierre
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
German Federal Ministry of Research, Technology and Space (Berlin); Fonds de recherche du Québec - Santé (FRQS); Instituto de Salud Carloss III (Spain); The French National Research Agency (France)
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Special Cases
Projecttitle
Multi-scale exploration of autoantibodies against synaptic receptors
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Team Grant: NEURON
Keyworddelim
Autoimmune Dysfunction; Bipolar Disorders; Cells Imaging; Induced Pluripotent Stem Cells; Mental Health; Schizophrenia
Abstract
Psychotic disorders (PDs) encompassing schizophrenia and bipolar disorders, are major health problems worldwide. Growing evidence suggest that these major psychoses have a neurodevelopmental component involving in particular synaptic imbalance mostly between glutamatergic and dopaminergic neurotransmitter systems. However, due to their complexity our understanding of PDs remains limited. It is well-established that several converging factors are involved in these complex PDs, among which immune status, including autoimmunity, are particularly relevant. A role for autoimmune dysfunction in PDs, reported in schizophrenia almost a century ago, is supported by specific autoimmune responses to selfantigens identified in particular in PD. The importance of autoimmunity in major psychosis has been strongly reinforced as a number of syndromes characterized by global encephalopathy and by more focal psychiatric symptoms was found to result from autoimmune dysfunction, caused by anti-neuronal antibodies that alter synaptic transmission, such as NMDARAb in encephalitis. Thus, the role of the autoimmunity against neuronal receptor targets in the pathogenesis of PDs has gained tremendous support over the last years and urgently requires multidisciplinary in-depth investigations to unravel the molecular mechanisms underlying psychosis and offer new therapeutic strategies. We identified that almost 20% of patients diagnosed with schizophrenia are seropositive for these autoantibodies, opening therapeutical options for these patients. Here, we plan to tackle such a major challenge in a unique, complementary and synergistic consortium of clinical and basic research experts, who strongly contributed to our current understanding of autoimmunity in brain disorders. Our objective is to uncover how NMDAR-Ab underliesPDs in seropositive NMDAR-Ab patients, using a unique and multi-scale combination of experimental approaches, from pre-clinical experiments to clinical exploration.
Competitiondate
201806
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Marquet, Pierre
Approvedterm
3 ans 0 mois
Cihrcontribution2
Inst of Neurosc Mental Hlth &A~ $100,000~ $0~